Pridopidine in treatment of Huntington's disease: Beyond chorea?

The Lancet Neurology

Volumn 10, Issue 12, 2011, Pages 1036-1037

  Feigin, Andrew ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRIDOPIDINE;

COGNITION; DOPAMINERGIC TRANSMISSION; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EYE HAND COORDINATION; EYE MOVEMENT; FUNCTIONAL STATUS; GAIT; HUMAN; HUNTINGTON CHOREA; LETTER; MOTOR PERFORMANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TOTAL MOTOR SCORE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; UNIFIED HUNTINGTON DISEASE RATING SCALE;

FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MOTOR ACTIVITY; PIPERIDINES;

EID: 81255150234     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70247-2     Document Type: Letter

References (5)

1. Huntington G On chorea. Med Surg Rep 1872, 26:320-321.
2. Peavy GM, Jacobson MW, Goldstein JL, et al. Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord 2010, 25:1163-1169.
3. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000, 54:452-458.
4. Garcia de Yebenes J, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease: a phase 3, randomised, placebo-controlled trial. Lancet Neurol 2011, for the MermaiHD study investigators, Published online Nov 8. 10.1016/S1474-4422(11)70233-2.
5. McGarry A, Kieburtz K, Rembratt A, Tedroff J A randomized, double-blind placebo-controlled trial of ACR16 in Huntington's disease. Neurotherapeutics 2011, 8:135. The Huntington Study Group HART Investigators.